Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-PLAQUE
2021-004601-47Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and non-obstructive coronary artery disease comparing Inclisiran plus maximally tolerated statin therapy with Placebo plus maximally tolerated statin therapy (2 arms). Primary endpoint: Percentage change from baseline to month 24 in total coronary atheroma volume. Started Mar 2022; status: active.
02
Drugs
inclisiran
03
Conditions
coronary arteriosclerosisnon-obstructive coronary artery disease
Beyond the preview
Go deeper on 2021-004601-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004601-47.